US2013331404A1PendingUtilityA1
Methods and Compositions for Inhibition of Polymerase
Est. expiryOct 15, 2030(~4.3 yrs left)· nominal 20-yr term from priority
A61P 31/14A61P 31/16A61K 45/06A61K 31/351A61K 31/215C07H 7/06A61K 31/519A61K 9/0019A61K 31/7064A61K 31/196C07D 487/04A61K 9/0053A61K 31/70Y02A50/30A61K 31/40
52
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention is directed to methods and compositions for inhibition of viral nucleic acid polymerases, such as RNA and DNA polymerases, and methods and compositions that are useful for treating viral infections in subjects. The methods comprise administering to the subject a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt or hydrate thereof, or a composition comprising a compound of formula I, or a pharmaceutically acceptable salt or hydrate thereof, and a pharmaceutically acceptable carrier. The composition or method may optionally comprise one or more additional anti-viral agents.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . A method for inhibition of a RNA viral polymerase in a subject which comprises administering to said subject a therapeutically effective amount of a compound of formula I:
wherein A is NH 2 or OH; and B is H or NH 2 ; or pharmaceutically acceptable salt or hydrate thereof.
2 - 4 . (canceled)
5 . The method of claim 1 , wherein the RNA viral polymerase is a polymerase selected from the group consisting of orthmyxoviridae, Paramyxoviridae, arenaviridae, bunyaviridae, flaviviridae, filoviridae, togaviridae, picornaviridae, and coronaviridae viral polymerases.
6 . The method of claim 1 , wherein the RNA viral polymerase is selected from the group consisting of adenovirus, rhinovirus, hepatitis, immunodeficiency virus, polio, measles, Ebola, Coxsackie, Rhino, West Nile, small pox, encephalitis, yellow fever, Dengue fever, influenza A, influenza B, lassa, lymphocytic choriomeningitis, junin, machuppo, guanarito, hantavirus, Rift Valley Fever, La Crosse, California encephalitis, Crimean-Congo, Marburg, Japanese Encephalitis, Kyasanur Forest, Venezuelan equine encephalitis, Eastern equine encephalitis, Western equine encephalitis, severe acute respiratory syndrome (SARS), parainfluenza, respiratory syncytial, Punta Toro, Tacaribe and pachindae viral polymerases.
7 . (canceled)
8 . The method of claim 1 , wherein the RNA viral polymerase is a polymerase selected from the group consisting of Ebola, yellow fever, Marburg, influenza A and influenza B viral polymerases.
9 - 15 . (canceled)
16 . The method of claim 1 , wherein A is NH 2 and B is H.
17 . (canceled)
18 . The method of claim 1 , wherein said subject is a mammal.
19 . The method of claim 18 , wherein said subject is a human.
20 . The method of claim 1 , further comprising administration of an additional anti-viral agent.
21 . The method of claim 20 , wherein the additional anti-viral agent is selected from the group consisting of laninamivir, oseltamivir, zanamivir, and peramivir.
22 . The method of claim 20 , wherein the additional anti-viral agent is peramivir.
23 . The method of claim 1 , wherein administration is selected from the group consisting of intravenous, intraperitoneal intramuscular and oral.
24 - 26 . (canceled)
27 . A method for treating a viral infection in a subject comprising administering to said subject a therapeutically effective amount of a compound of formula I:
wherein A is NH 2 or OH; and B is H or NH 2 ; or pharmaceutically acceptable salt or hydrate thereof.
28 . (canceled)
29 . The method of claim 27 , wherein A is NH 2 and B is H.
30 . (canceled)
31 . The method of claim 27 , wherein the viral infection comprises a virus selected from the group consisting of orthmyxoviridae, Paramyxoviridae, arenaviridae, bunyaviridae, flaviviridae, filoviridae, togaviridae, picornaviridae, and coronaviridae families.
32 . The method of claim 27 , wherein the viral infection is selected from the group consisting of adenovirus, rhinovirus, hepatitis, immunodeficiency virus, polio, measles, Ebola, Coxsackie, Rhino, West Nile, small pox, encephalitis, yellow fever, Dengue fever, influenza A, influenza B, lassa, lymphocytic choriomeningitis, junin, machuppo, guanarito, hantavirus, Rift Valley Fever, La Crosse, California encephalitis, Crimean-Congo, Marburg, Japanese Encephalitis, Kyasanur Forest, Venezuelan equine encephalitis, Eastern equine encephalitis, Western equine encephalitis, severe acute respiratory syndrome (SARS), parainfluenza, respiratory syncytial, Punta Toro, Tacaribe and pachindae viruses.
33 . (canceled)
34 . The method of claim 27 , wherein the viral infection is selected from the group consisting of Ebola, yellow fever, Marburg, influenza A and influenza B viruses.
35 - 41 . (canceled)
42 . The method of claim 27 , further comprising administration of an additional anti-viral agent.
43 . The method of claim 42 , wherein the additional anti-viral agent is selected from the group consisting of laninamivir, oseltamivir, zanamivir, and peramivir.
44 . The method of claim 42 , wherein the additional anti-viral agent is peramivir.
45 . The method of claim 27 , wherein administration is selected from the group consisting of intravenous, intraperitoneal intramuscular, and oral.
46 - 48 . (canceled)
49 . A method for suppressing a viral infection in a subject which comprises administering to the subject a therapeutically effective amount of a compound of formula I:
wherein A is NH 2 or OH; and B is H or NH 2 ; or pharmaceutically acceptable salt or hydrate thereof.
50 . (canceled)
51 . The method of claim 49 , wherein A is NH 2 and B is H.
52 . (canceled)
53 . The method of claim 49 , wherein the viral infection comprises a virus selected from the group consisting of orthmyxoviridae, Paramyxoviridae, arenaviridae, bunyaviridae, flaviviridae, filoviridae, togaviridae, picornaviridae, and coronaviridae families.
54 . The method of claim 49 , wherein the viral infection is selected from the group consisting of adenovirus, rhinovirus, hepatitis, immunodeficiency virus, polio, measles, Ebola, Coxsackie, Rhino, West Nile, small pox, encephalitis, yellow fever, Dengue fever, influenza A, influenza B, lassa, lymphocytic choriomeningitis, junin, machuppo, guanarito, hantavirus, Rift Valley Fever, La Crosse, California encephalitis, Crimean-Congo, Marburg, Japanese Encephalitis, Kyasanur Forest, Venezuelan equine encephalitis, Eastern equine encephalitis, Western equine encephalitis, severe acute respiratory syndrome (SARS), parainfluenza, respiratory syncytial, Punta Toro, Tacaribe and pachindae.
55 . (canceled)
56 . The method of 49 , wherein the viral infection is selected from the group consisting of Ebola, yellow fever, Marburg, influenza A and influenza B viruses.
57 - 63 . (canceled)
64 . The method of claim 49 , further comprising administration of an additional anti-viral agent.
65 . The method of claim 64 , wherein the additional anti-viral agent is selected from the group consisting of laninamivir, oseltamivir, zanamivir, and peramivir.
66 . The method of claim 64 , wherein the additional anti-viral agent is peramivir.
67 . The method of claim 49 , wherein administration is selected from the group consisting of intravenous, intraperitoneal, intramuscular, and oral.
68 - 70 . (canceled)
71 . A method for preventing a viral infection in a subject comprising administering to the subject a therapeutically effective amount of a compound of formula I:
wherein A is NH 2 or OH; and B is H or NH 2 ; or pharmaceutically acceptable salt or hydrate thereof.
72 . (canceled)
73 . The method of claim 71 , wherein A is NH 2 and B is H.
74 . (canceled)
75 . The method of claim 71 , wherein the viral infection comprises a virus selected from the group consisting of orthmyxoviridae, Paramyxoviridae, arenaviridae, bunyaviridae, flaviviridae, filoviridae, togaviridae, picornaviridae, and coronaviridae families.
76 . The method of claim 71 , wherein said viral infection comprises infection with one or more virus selected from the group consisting of adenovirus, rhinovirus, hepatitis, immunodeficiency virus, polio, measles, Ebola, Coxsackie, Rhino, West Nile, small pox, encephalitis, yellow fever, Dengue fever, influenza A, influenza B, lassa, lymphocytic choriomeningitis, junin, machuppo, guanarito, hantavirus, Rift Valley Fever, La Crosse, California encephalitis, Crimean-Congo, Marburg, Japanese Encephalitis, Kyasanur Forest, Venezuelan equine encephalitis, Eastern equine encephalitis, Western equine encephalitis, severe acute respiratory syndrome (SARS), parainfluenza, respiratory syncytial, Punta Toro, Tacaribe and pachindae viruses.
77 . (canceled)
78 . The method of claim 71 , wherein the viral infection is selected from the group consisting of Ebola, yellow fever, Marburg, influenza A and influenza B viruses.
79 - 85 . (canceled)
86 . The method of claim 71 , further comprising administration of an additional anti-viral agent.
87 . The method of claim 86 , wherein the additional anti-viral agent is selected from the group consisting of laninamivir, oseltamivir, zanamivir, and peramivir.
88 . The method of claim 86 , wherein the additional anti-viral agent is peramivir.
89 . The method of claim 71 , wherein administration is selected from the group consisting of intravenous, intraperitoneal, intramuscular, and oral.
90 - 92 . (canceled)
93 . The method of claim 27 , wherein the subject is a mammal.
94 . The method of claim 49 , wherein the subject is a mammal.
95 . The method of claim 71 , wherein the subject is a mammal.
96 . The method of claim 27 , wherein the subject is a human.
97 . The method of claim 49 , wherein the subject is a human.
98 . The method of claim 71 , wherein the subject is a human.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.